This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2004 Jul 29;351(5):501-5.

doi: 10.1056/NEJMsb040064.

Beyond fast track for drug approvals

Thomas G Roberts Jr¹, Bruce A Chabner

Affiliations

PMID: 15282359
DOI: 10.1056/NEJMsb040064

Beyond fast track for drug approvals

Thomas G Roberts Jr et al. N Engl J Med. 2004.

. 2004 Jul 29;351(5):501-5.

doi: 10.1056/NEJMsb040064.

Authors

Thomas G Roberts Jr¹, Bruce A Chabner

Affiliation

¹ Division of Hematology-Oncology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA. troberts@partners.org

PMID: 15282359
DOI: 10.1056/NEJMsb040064

No abstract available

PubMed Disclaimer

Similar articles

Assessing supplement safety--the FDA's controversial proposal.
Cohen PA. Cohen PA. N Engl J Med. 2012 Feb 2;366(5):389-91. doi: 10.1056/NEJMp1113325. Epub 2012 Jan 25. N Engl J Med. 2012. PMID: 22276780 No abstract available.
Good drug, bad luck: business, regulatory issues can create obstacles for drug development.
Goldman B. Goldman B. J Natl Cancer Inst. 2004 Nov 3;96(21):1573-4. doi: 10.1093/jnci/96.21.1573. J Natl Cancer Inst. 2004. PMID: 15523084 No abstract available.
The drug that could have been.
Schultz S. Schultz S. US News World Rep. 2002 Aug 19;133(7):18, 20-3. US News World Rep. 2002. PMID: 12195678 No abstract available.
Key factors in the rising cost of new drug discovery and development.
Dickson M, Gagnon JP. Dickson M, et al. Nat Rev Drug Discov. 2004 May;3(5):417-29. doi: 10.1038/nrd1382. Nat Rev Drug Discov. 2004. PMID: 15136789 Review. No abstract available.
Triazolam treatment controversy.
Ghaeli P, Dufresne RL, Stoukides CA. Ghaeli P, et al. Ann Pharmacother. 1994 Sep;28(9):1038-40. Ann Pharmacother. 1994. PMID: 7803879 Review. No abstract available.

See all similar articles

Cited by

The politics and bio-ethics of regulatory trust: case-studies of pharmaceuticals.
Abraham J. Abraham J. Med Health Care Philos. 2008 Dec;11(4):415-26. doi: 10.1007/s11019-008-9155-x. Epub 2008 Jul 22. Med Health Care Philos. 2008. PMID: 18649014
In the end what matters most? A review of clinical endpoints in advanced breast cancer.
Verma S, McLeod D, Batist G, Robidoux A, Martins IR, Mackey JR. Verma S, et al. Oncologist. 2011;16(1):25-35. doi: 10.1634/theoncologist.2010-0278. Epub 2011 Jan 6. Oncologist. 2011. PMID: 21212428 Free PMC article. Review.
Regulatory Pathways Supporting Expedited Drug Development and Approval in ICH Member Countries.
Franco P, Jain R, Rosenkrands-Lange E, Hey C, Koban MU. Franco P, et al. Ther Innov Regul Sci. 2023 May;57(3):484-514. doi: 10.1007/s43441-022-00480-3. Epub 2022 Dec 3. Ther Innov Regul Sci. 2023. PMID: 36463352 Free PMC article. Review.
Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.
Apolone G, Joppi R, Bertele' V, Garattini S. Apolone G, et al. Br J Cancer. 2005 Sep 5;93(5):504-9. doi: 10.1038/sj.bjc.6602750. Br J Cancer. 2005. PMID: 16136026 Free PMC article.
Biomedical journal editing: elements of success.
Gasparyan AY, Ayvazyan L, Kitas GD. Gasparyan AY, et al. Croat Med J. 2011 Jun;52(3):423-8. doi: 10.3325/cmj.2011.52.423. Croat Med J. 2011. PMID: 21674841 Free PMC article. No abstract available.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.